NRCM
NKGN

Northern Right Capital Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Northern Right Capital Management’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-150,000
Closed -$1.45M – 44
2021
Q4 		$1.45M Hold
150,000
– – 0.44% 34
2021
Q3 		$1.45M Buy
+150,000
New +$1.46M 0.43% 40

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Northern Right Capital Management's NKGN Position: Q1 2022 in Review

Northern Right Capital Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2022, closing a stake of 150,000 shares — an estimated $1.45M sold.

Northern Right Capital Management first reported a position in NKGN in Q3 2021 and held it in 2 quarters. The position peaked at $1.45M in Q3 2021. 43 funds tracked by Wall St. Rank hold NKGN as of Q1 2022.

  • Northern Right Capital Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Northern Right Capital Management sold 150,000 NKGen Biotech, Inc. Common Stock shares in Q1 2022, an estimated $1.45M.
  • Northern Right Capital Management first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Northern Right Capital Management's NKGen Biotech, Inc. Common Stock position peaked at $1.45M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2022.

Based on Northern Right Capital Management's 13F filing for Q1 2022, filed 16 May 2022.